论文部分内容阅读
目的:观察FOLFOX方案治疗晚期胃癌的临床疗效。方法:33例晚期胃癌患者采用奥沙利铂联合5-氟尿嘧啶及亚叶酸钙治疗(FOLFOX方案),2个周期后评价疗效、临床受益反应、毒副反应及免疫功能。结果:治疗2个周期后,总有效率为42.42%,临床受益反应有效率为69.69%;主要的毒副反应为骨髓抑制、胃肠道反应、神经毒性等,大多为1-2级;化疗后CD4+、CD4+/CD8+较化疗前明显升高(P<0.05),CD3+、CD8+、CD19+细胞与化疗前比较无明显变化(P>0.05)。结论:FOLFOX方案治疗晚期胃癌疗效可靠,毒性反应轻,患者可以耐受。
Objective: To observe the clinical efficacy of FOLFOX regimen in the treatment of advanced gastric cancer. Methods: Thirty-three patients with advanced gastric cancer were treated with oxaliplatin combined with 5-fluorouracil and leucovorin (FOLFOX regimen). The efficacy, clinical benefit response, toxicity and immune function were evaluated after 2 cycles. Results: After 2 cycles of treatment, the total effective rate was 42.42%, and the effective rate of clinical beneficiary response was 69.69%. The main toxicities and side effects were myelosuppression, gastrointestinal reactions, and neurotoxicity, and most of them were grade 1-2; After CD4+ and CD4+/CD8+, the levels of CD4+ and CD4+/CD8+ cells were significantly higher than before chemotherapy (P<0.05), and CD3+, CD8+, and CD19+ cells had no significant changes compared with those before chemotherapy (P>0.05). Conclusion: The FOLFOX regimen is a reliable and effective treatment for advanced gastric cancer. The toxicity is light and the patient can tolerate it.